Anti-Melanoma gp100 抗体 [HMB45], prediluted (ab906)
製品の概要
-
製品名Anti-Melanoma gp100 antibody [HMB45], prediluted
Melanoma gp100 一次抗体 製品一覧 -
製品の詳細Mouse monoclonal [HMB45] to Melanoma gp100, prediluted
-
由来種Mouse
-
特異性This antibody reacts with a neuraminidase sensitive oligosaccharide side chain of a glycoconjugate present in immature melanosomes. It reacts with junctional and blue nevus cells. Non-melanocytic cells are negative.
-
アプリケーション適用あり: IHC-P, IHC-Frmore details
-
種交差性交差種: Human
-
免疫原
Tissue, cells or virus corresponding to Human Melanoma gp100. BALB/C mice were injected with extract of pigmented malanoma metastases from lymph nodes.
Database link: P40967 -
ポジティブ・コントロール
- Melanoma
製品の特性
-
製品の状態Liquid
-
保存方法Shipped at 4°C. Store at +4°C. Do Not Freeze.
-
バッファーPreservative: 0.05% Sodium azide
Inert stabilizer -
Concentration information loading...
-
ポリ/モノモノクローナル
-
クローン名HMB45
-
ミエローマunknown
-
アイソタイプIgG1
-
軽鎖の種類kappa
-
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
アプリケーション
Our Abpromise guarantee covers the use of ab906 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-P | Use at an assay dependent concentration. | |
IHC-Fr | Use at an assay dependent concentration. |
ターゲット情報
-
機能Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.
-
組織特異性Preferentially expressed in melanomas. Some expression was found in dysplastic nevi. Not found in normal tissues nor in carcinomas. Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth.
-
配列類似性Belongs to the PMEL/NMB family.
Contains 1 PKD domain. -
ドメインThe RPT domain is essential for the generation of the fibrillar matrix of melanosomes.
The lumenal domain is necessary for correct processing and trafficking to melanosomes. -
翻訳後修飾A small amount of P1/P100 (major form) undergoes glycosylation to yield P2/P120 (minor form). P2 is cleaved by a furin-like proprotein convertase (PC) in a pH-dependent manner in a post-Golgi, prelysosomal compartment into two disulfide-linked subunits: a large lumenal subunit, M-alpha/ME20-S, and an integral membrane subunit, M-beta. Despite cleavage, only a small fraction of M-alpha is secreted, whereas most M-alpha and M-beta remain associated with each other intracellularly. M-alpha is further processed to M-alpha N and M-alpha C. M-alpha C further undergoes processing to yield M-alpha C1 and M-alpha C3 (M-alpha C2 in the case of PMEL17-is or PMEL17-ls). Formation of intralumenal fibrils in the melanosomes requires the formation of M-alpha that becomes incorporated into the fibrils. Stage II melanosomes harbor only Golgi-modified Pmel17 fragments that are derived from M-alpha and that bear sialylated O-linked oligosaccharides.
N-glycosylated. O-glycosylated; contains sialic acid. -
細胞内局在Secreted and Endoplasmic reticulum membrane. Golgi apparatus. Melanosome. Endosome > multivesicular body. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes.
- Information by UniProt
-
参照データベース
- Entrez Gene: 6490 Human
- Omim: 155550 Human
- SwissProt: P40967 Human
- Unigene: 95972 Human
-
別名
- 95 kDa melanocyte specific secreted glycoprotein antibody
- 95 kDa melanocyte-specific secreted glycoprotein antibody
- D12S53E antibody
see all
データシートおよび資料
参考文献
ab906 has not yet been referenced specifically in any publications.